DBV Technologies Files Annual Report, Reflects Financial Stability
DBV Technologies Files Annual Report and Universal Registration Document
DBV Technologies, a prominent biopharmaceutical firm in the clinical stage, has recently taken a significant step by filing its Annual Report on Form 10-K along with its Universal Registration Document (URD). Focused primarily on innovative treatment options for food allergies and various immunologic conditions, the organization is deeply committed to addressing the substantial unmet medical needs faced by patients.
Financial Overview and Approval
The Board of Directors met and meticulously approved the audited financial statements for the year ending on December 31, presenting solid results and reflecting previous unaudited assessments released in March. This approval signifies the Company’s transparency and commitment to clear communication with stakeholders about its financial health.
Key Filing Details
Integral to these filings is the Annual Report on Form 10-K submitted to the U.S. Securities and Exchange Commission (SEC) as well as the URD presented to the French market authority, Autorité des Marchés Financiers (AMF). These documents encapsulate the Company's performance and governance, showcasing its commitment to regulatory compliance and investor engagement.
Contents of the URD
The URD offers a comprehensive overview mandated by French law, outlining crucial elements including:
- The Annual Financial Report;
- The Management Report;
- The Corporate Governance Report; and
- An explanation of the Share Buyback Program.
These documents can be accessed freely on the Investors section of the Company’s website, ensuring easy access for all interested parties.
DBV Technologies' Mission and Commitment
DBV Technologies is driven by a mission to develop innovative therapies for food allergies, making a meaningful impact on the lives of those affected by these conditions. The Company is diligently investigating the usage of its proprietary VIASKIN® patch technology, focused on treating food allergies through epicutaneous immunotherapy (EPIT™). This method aims to modify the immune response to allergens through a non-invasive approach, thereby helping individuals build tolerance to allergens.
With millions of individuals, particularly young children, living with food allergies, DBV's approach presents a transformative avenue for treatment. Their ongoing clinical trials, especially those involving VIASKIN Peanut for peanut-allergic toddlers and children, exemplify the Company's focus on innovative, research-driven solutions designed to improve patient care and outcomes.
Company Operations
Headquartered in Châtillon, France, DBV Technologies operates on both sides of the Atlantic, with additional facilities in North America, specifically in Warren, New Jersey. The Company’s shares are actively traded on Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), as well as its American Depositary Shares (ADSs) on the Nasdaq Capital Market (Ticker: DBVT).
Contact Information for Investors and Media
As part of their commitment to maintaining open lines of communication with stakeholders, DBV Technologies provides direct contacts for inquiries:
Investor Contact
Katie Matthews
DBV Technologies
Email: katie.matthews@dbv-technologies.com
Media Contact
Angela Marcucci
DBV Technologies
Email: angela.marcucci@dbv-technologies.com
Frequently Asked Questions
What is the purpose of the Annual Report filed by DBV Technologies?
The Annual Report outlines the Company’s financial performance and operational highlights, providing transparency to shareholders and stakeholders.
What innovative treatment is DBV Technologies developing?
DBV Technologies is focusing on the development of the VIASKIN® patch technology for treating food allergies through non-invasive epicutaneous immunotherapy.
Where can I access DBV Technologies’ financial documents?
The financial documents can be accessed on the Investor section of DBV’s official website.
What are DBV Technologies’ main research focuses?
The company primarily concentrates on treatments for food allergies and immunologic conditions, striving to address significant unmet medical needs.
How does DBV’s adhesive patch technology work?
The VIASKIN® patch technology delivers microgram quantities of a biologically active compound through the skin, enhancing the immune system's ability to tolerate allergens.
About The Author
Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
